According to Pfizer, the vial content did not dissolve when reconstituted, and discrepancies were noted in the crimp code, which did not match the reported production documentation batch.
The production process also failed to meet Pfizer's specifications, posing a significant risk to patients as the quality and safety of the counterfeit product are not guaranteed.
NAFDAC emphasized the importance of obtaining medical products from authorized/licensed suppliers, urging healthcare providers and patients to carefully check product authenticity and physical condition before purchase and administration.
The agency warned against illegal importation, distribution, and sale of the counterfeit Meronem 1g injection, urging vigilance within the supply chain.
Anyone in possession of the counterfeit product is advised to stop using it and submit it to the nearest NAFDAC office.
Those who have used the product or experienced adverse reactions are encouraged to seek immediate medical advice. Healthcare professionals and consumers are urged to report suspicions of adverse drug reactions or substandard medicines to NAFDAC through various channels, including phone numbers, email, and reporting platforms on the NAFDAC website.
The public is also encouraged to report adverse effects using the Med-safety application available for download on Android and IOS stores or via email.